Loading clinical trials...
Loading clinical trials...
A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects
Conditions
Interventions
MB12066
MB12066
+3 more
Locations
1
South Korea
Clinical Research Institute of Seoul National University Hospital
Seoul, Daehang-ro, Jongno-Gu, South Korea
Start Date
April 1, 2011
Primary Completion Date
April 1, 2012
Completion Date
April 1, 2012
Last Updated
December 21, 2017
NCT01143454
NCT07472881
NCT07010757
NCT06223555
NCT06989203
NCT07237750
Lead Sponsor
Yungjin Pharm. Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions